Nicola Broughton

Nicola Broughton has a diverse work experience in various roles and companies. In 2019, they served as a Non-Executive Director at IN-PART. From 2015 to 2020, they held multiple roles at MIP Diagnostics Limited, including Non-Executive Director. From 2015 to 2020, they also worked at Mercia Asset Management PLC, where they served as Investment Director and Head of Universities, and later as Fund Principal for Mercia Fund 1. In 2020, they founded Nicola Broughton Consulting Ltd, where they currently work as a Managing Director, providing advice and support to clients in commercializing technologies and investing in early-stage University companies. In the same year, they co-founded and became a Venture Partner at Óskare Capital. In 2021, they took on roles as Chairwoman and Director at Wobble Genomics, and in 2022, they became a Non-Executive Director at both QUBIS Ltd and Cytomos. Finally, in 2022, they became the Chief Business Officer at Nodus Oncology, and currently serves as the Chief Business Officer at Cumulus Oncology while also working as a Consultant Strategic Advisor and NXD.

Nicola Broughton's education history begins in 1990 when they attended the University of Oxford. Nicola completed their Bachelor of Arts (B.A.) degree in Biochemistry in 1994. Following that, they pursued further studies in the field of Biochemistry and completed their Doctor of Philosophy (Ph.D.) at King's College London from 1994 to 1998. In 1999, Nicola attended Northumbria University and obtained their Master of Business Administration (MBA) degree. The specific field of study for their MBA is not provided. Lastly, in 2011 to 2012, Nicola attended the National Association of Paralegals and received a Diploma in Law. No field of study is specified for this diploma.